Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants

Abstract

AbstractAvacopan, a complement 5a receptor (C5aR) antagonist approved for treating severe active antineutrophil cytoplasmic autoantibody (ANCA)‐associated vasculitis, was evaluated in 2 clinical drug‐drug interaction studies. The studies assessed the impact of avacopan on the pharmacokinetics (PK) of CYP3A4 substrates midazolam and simvastatin and CYP2C9 substrate celecoxib, and the influence of CYP3A4 inhibitor itraconazole and inducer rifampin on the PKs of avacopan. The results indicated that twice‐daily oral administration of 30 mg of avacopan increased the area under the curve (AUC) of midazolam by 1.81‐fold and celecoxib by 1.15‐fold when administered without food, and twice‐daily oral administration of 30 or 60 mg of avacopan increased the AUC of simvastatin by approximately 2.6‐3.5‐fold and the AUC of the active metabolite β‐hydroxy‐simvastatin acid by approximately 1.4‐1.7‐fold when co‐administered with food. Furthermore, the AUC of avacopan increased by approximately 2.19‐fold when co‐administered with itraconazole and decreased by approximately 13.5‐fold when co‐administered with rifampin. These findings provide critical insights into the potential drug‐drug interactions involving avacopan, which could have significant implications for patient care and treatment planning. (NCT06207682)